Want to see HK:2197 full AI Analyst Report?
Top Page
Clover Biopharmaceuticals Ltd.
(2197)
Select Model
Select Model
Rating:50Neutral
Price Target:
HK$2.00
▼(-15.61% Downside)
Action:Reiterated
Date:08/08/26
The score is held down primarily by very weak financial performance (revenue collapse, sustained losses, negative equity, and ongoing cash burn). Positive price momentum and trend indicators provide a meaningful offset, while valuation offers limited support due to negative earnings and no dividend yield data.
Positive Factors
Proprietary Trimer-Tag platform
Owning a proprietary Trimer-Tag recombinant protein platform provides a durable technical differentiation for vaccine design and manufacturing. This can accelerate candidate development, enable reuse across antigens, and support future licensing or partnerships, sustaining long-term competitive advantage.
Negative Factors
Severe 2025 revenue collapse (~93%)
A ~93% revenue decline in 2025 represents a structural loss of commercial traction or one-off revenue removal that undermines sustainable operations. Such a collapse weakens the revenue base, impedes fixed-cost absorption, and materially raises the need for strategic restructuring or external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Trimer-Tag platform
Owning a proprietary Trimer-Tag recombinant protein platform provides a durable technical differentiation for vaccine design and manufacturing. This can accelerate candidate development, enable reuse across antigens, and support future licensing or partnerships, sustaining long-term competitive advantage.
Read all positive factors
Clover Biopharmaceuticals Ltd. (2197) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.73B
Dividend YieldN/A
Average Volume (3M)4.68M
Price to Earnings (P/E)2.7
Beta (1Y)2.50
Revenue Growth-99.15%
EPS GrowthN/A
CountryHK
Employees257
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.66
Shares Outstanding1,298,600,700
10 Day Avg. Volume2,128,877
30 Day Avg. Volume4,680,807
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)-1.47
Price to Sales (P/S)775.86
P/FCF Ratio-13.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Clover Biopharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on discovering, developing, and commercializing innovative vaccines and biological therapies. Their efforts target infectious diseases, various cancers, and autoimmune condition...
How the Company Makes Money
Clover Biopharmaceuticals generates revenue primarily from the development and commercialization of vaccine products, alongside collaboration- and licensing-related income where applicable.
Key revenue streams include:
1) Product sales (vaccines ...
Clover Biopharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 423.34K | 3.41M | 38.42M | 39.26M | 0.00 | 0.00 |
| Gross Profit | -38.52M | -23.85M | -672.94M | 24.24M | -475.64M | -66.27M |
| EBITDA | -245.56M | -221.24M | -916.54M | -45.07M | -2.37B | -2.23B |
| Net Income | 843.28M | -199.78M | -903.43M | -138.54M | -2.45B | -6.02B |
Balance Sheet | ||||||
| Total Assets | 241.79M | 458.12M | 812.74M | 2.10B | 4.69B | 5.35B |
| Cash, Cash Equivalents and Short-Term Investments | 104.77M | 286.15M | 427.53M | 766.26M | 1.64B | 2.87B |
| Total Debt | 2.08M | 10.62M | 89.64M | 334.45M | 354.37M | 67.92M |
| Total Liabilities | 1.04B | 2.26B | 2.45B | 2.83B | 5.36B | 4.13B |
| Stockholders Equity | -801.06M | -1.80B | -1.64B | -732.83M | -668.14M | 1.22B |
Cash Flow | ||||||
| Free Cash Flow | -79.64M | -190.55M | -290.11M | -737.05M | -1.80B | -998.07M |
| Operating Cash Flow | -79.64M | -190.52M | -288.49M | -727.88M | -1.69B | -917.75M |
| Investing Cash Flow | -1.72M | -11.69K | 3.17M | -6.16M | -37.51M | 112.12M |
| Financing Cash Flow | -142.87M | -76.59M | -51.50M | -142.41M | 483.14M | 3.06B |
Clover Biopharmaceuticals Ltd. Technical Analysis
Neutral
2.37
Price Trends
1.94
Positive
2.16
Negative
2.30
Negative
Market Momentum
0.02
Positive
48.85
Neutral
16.94
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2197, the sentiment is Neutral. The current price of 2.37 is above the 20-day moving average (MA) of 2.26, above the 50-day MA of 1.94, and above the 200-day MA of 2.30, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 48.85 is Neutral, neither overbought nor oversold. The STOCH value of 16.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2197.
Clover Biopharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$38.22B | 37.75 | 20.41% | ― | 32.63% | 8.87% | |
59 Neutral | HK$3.40B | 4.71 | 10.99% | ― | 1417.68% | 660.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$2.73B | 2.72 | -64.89% | ― | -99.15% | ― | |
46 Neutral | HK$671.68M | -3.33 | -7.32% | ― | ― | 51.71% | |
44 Neutral | HK$2.29B | -2.98 | -24.66% | ― | -18.45% | -151.15% | |
37 Underperform | HK$3.11B | -5.56 | -79.24% | ― | -82.46% | 41.19% |
* Healthcare Sector Average
HK:2197
Clover Biopharmaceuticals Ltd.
2.19
0.26
13.21%
HK:2137
Brii Biosciences Limited
0.90
-1.33
-59.64%
HK:6998
Genor Biopharma Holdings Limited
1.69
-3.27
-65.96%
HK:2179
Jiangsu Recbio Technology Co., Ltd. Class H
5.00
-2.50
-33.33%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
65.55
-23.15
-26.10%
HK:6660
AIM Vaccine Co., Ltd. Class H
1.77
-3.32
-65.23%
Clover Biopharmaceuticals Ltd. Corporate Events
Clover Biopharmaceuticals Swings to Profit on GAVI Gain as Cash Levels Tighten
Aug 25, 2026
Clover Biopharmaceuticals reported a sharp swing to profit for the six months ended June 30, 2026, posting net income of about RMB955 million versus a loss of RMB101 million a year earlier. The turnaround was driven mainly by a one-off accounting ...
Clover Biopharmaceuticals Sets Board Meeting to Approve Interim Results and Consider Dividend
Aug 13, 2026
Clover Biopharmaceuticals has scheduled a board meeting for August 25, 2026, to review and approve the interim results for the six months ended June 30, 2026. The board will also consider the potential declaration of an interim dividend, signaling...
Clover Biopharmaceuticals Signals Interim Profit on One-Off Gavi Settlement Gain
Jul 19, 2026
Clover Biopharmaceuticals has issued a positive profit alert, indicating it expects to report a net profit of about RMB957 million to RMB1.204 billion for the first half of 2026, reversing a loss of roughly RMB101.3 million a year earlier. The swi...
Clover Biopharmaceuticals Wins Shareholder Backing for All AGM Resolutions
Jun 18, 2026
Clover Biopharmaceuticals reported that all resolutions at its annual general meeting on June 18, 2026, were approved by shareholders via poll, including the adoption of audited financial statements for the year ended December 31, 2025. Shareholde...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.